Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.53−0.08 (-4.97%)
Close on Nov 18, 2026Market cap $3.59MP/E –Yield –
Xenetic Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Xenetic Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$2.31M. For fiscal 2025 it was -$2.29M. The highest annual figure on record is $1.49M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.29M | – |
| FY2024 | Dec 31, 2024 | -$2.82M | – |
| FY2023 | Dec 31, 2023 | -$4.11M | – |
| FY2022 | Dec 31, 2022 | -$4.65M | – |
| FY2021 | Dec 31, 2021 | -$4.74M | – |
| FY2020 | Dec 31, 2020 | -$4.27M | – |
| FY2019 | Dec 31, 2019 | -$6.40M | – |
| FY2018 | Dec 31, 2018 | -$6.46M | -532.6% |
| FY2017 | Dec 31, 2017 | $1.49M | – |
| FY2016 | Dec 31, 2016 | -$8.79M | – |
| FY2015 | Dec 31, 2015 | -$5.30M | – |
| FY2014 | Dec 31, 2014 | -$12.68M | – |
| FY2013 | Dec 31, 2013 | -$6.05M | – |
| FY2012 | Dec 31, 2012 | -$6.26M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$875.49K | – |
| Q1 FY2026 | Mar 31, 2026 | -$536.38K | – |
| Q4 FY2025 | Dec 31, 2025 | -$242.68K | – |
| Q3 FY2025 | Sep 30, 2025 | -$658.25K | – |
| Q2 FY2025 | Jun 30, 2025 | -$383.83K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$673.99K | – |
| Q3 FY2024 | Sep 30, 2024 | -$459.04K | – |
| Q2 FY2024 | Jun 30, 2024 | -$525.10K | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$793.03K | – |
| Q3 FY2023 | Sep 30, 2023 | -$949.63K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.27M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$728.90K | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.03M | – |
| Q2 FY2021 | Jun 30, 2021 | -$726.81K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$953.66K | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.68M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.05M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.25M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.04M | -121.5% |
| Q3 FY2018 | Sep 30, 2018 | -$1.67M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.67M | -693.6% |
| Q4 FY2017 | Dec 31, 2017 | $4.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.64M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.99M | – |
| Q1 FY2017 | Mar 31, 2017 | $280.81K | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.62M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.03M | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.36M | – |
See a number that looks wrong?